Risk Stratification For and Use of DOAC Therapies for Stroke Prevention in Patient with Atrial Fibrillation

Caturano, Alfredo; Galiero, Raffaele; Spiezia, Serenella; Pafundi, Pia Clara

doi:10.1007/978-3-030-74462-5_6

Risk Stratification For and Use of DOAC Therapies for Stroke Prevention in Patient with Atrial Fibrillation

Alfredo Caturano⁶,
Raffaele Galiero⁶,
Serenella Spiezia⁶ &
…
Pia Clara Pafundi⁶

Chapter
First Online: 29 June 2021

1057 Accesses

Abstract

Atrial fibrillation (AF) is the most common arrhythmia, complicated by a fivefold increased risk of ischemic stroke due to thromboembolism. Anticoagulant agents play a key role in preventing this complication. Through years, several risk stratification algorithms have been investigated, while others are still object of debate. According to current guidelines, CHA2DS2VASc score and HAS-BLED score are the ones suggested for stroke and bleeding risk stratification, respectively. The improvement of knowledge and, eventually, the validation of novel risk score systems may lead to a better risk stratification and tailored therapy. Up to now, direct oral anticoagulants (DOACs) are recommended over warfarin for stroke prevention in high risk patients with non-valvular atrial fibrillation. In fact, DOACs demonstrated an efficacy equal to Vitamin K Antagonists (VKAs) in the prevention of both stroke and major embolic events, net of a lower bleeding risk. This finding has also been established by both post-marketing phase IV trials and real-world evidence. However, no comparative study among the four DOACs has been conducted yet. In this chapter, we will assess the main features of each DOAC and their use in specific clinical scenarios, according to the most commonly used risk scale systems.

This is a preview of subscription content, log in via an institution.

Chapter: USD 29.95; Price excludes VAT (USA)

eBook: USD 89.00; Price excludes VAT (USA)

Softcover Book: USD 119.99; Price excludes VAT (USA)

Hardcover Book: USD 169.99; Price excludes VAT (USA)

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

Abumuaileq RR, Abu-Assi E, López-López A, Raposeiras-Roubin S, Rodríguez-Mañero M, Martínez-Sande L, et al. Comparison between CHA2DS2-VASc and the new R2CHADS2 and ATRIA scores at predicting thromboembolic event in non-anticoagulated and anticoagulated patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord. 2015;15:156. Published 2015 Nov 19. https://doi.org/10.1186/s12872-015-0149-3.
Article CAS PubMed PubMed Central Google Scholar
Adam SS, McDuffie JR, Ortel TL, Williams JW Jr. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med. 2012;157(11):796–807. https://doi.org/10.7326/0003-4819-157-10-201211200-00532.
Article PubMed Google Scholar
Almutairi AR, Zhou L, Gellad WF, Lee JK, Slack MK, Martin JR, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: a systematic review and meta-analyses. Clin Ther. 2017;39(7):1456–1478.e36. https://doi.org/10.1016/j.clinthera.2017.05.358.
Article CAS PubMed Google Scholar
Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY. Chronic kidney disease is associated with the incidence of atrial fibrillation. Circulation. 2011;123(25):2946–53. https://doi.org/10.1161/CIRCULATIONAHA.111.020982.
Article PubMed PubMed Central Google Scholar
AlTurki A, Marafi M, Russo V, Proietti R, Essebag V. Subclinical atrial fibrillation and risk of stroke: past, present and future. Medicina (Kaunas). 2019;55(10):611. https://doi.org/10.3390/medicina55100611.
Article Google Scholar
Amin A, Garcia Reeves A, Li X, Dhamane A, Luo X, Di Fusco M, et al. Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure. PLoS One. 2019;14(3):e0213614. Published 2019 Mar 25. https://doi.org/10.1371/journal.pone.0213614.
Article CAS PubMed PubMed Central Google Scholar
Aspberg S, Chang Y, Atterman A, Bottai M, Go AS, Singer DE. Comparison of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation. Eur Heart J. 2016;37(42):3203–10. https://doi.org/10.1093/eurheartj/ehw077.
Article PubMed Google Scholar
Ballestri S, Capitelli M, Fontana MC, Arioli D, Romagnoli E, Graziosi C, et al. Direct oral anticoagulants in patients with liver disease in the era of non-alcoholic fatty liver disease global epidemic: a narrative review. Adv Ther. 2020;37(5):1910–32. https://doi.org/10.1007/s12325-020-01307-z.
Article PubMed PubMed Central Google Scholar
Berg DD, Ruff CT, Jarolim P, Giugliano RP, Nordio F, Lanz HJ, et al. Performance of the ABC scores for assessing the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in ENGAGE AF-TIMI 48. Circulation. 2019;139(6):760–71. https://doi.org/10.1161/CIRCULATIONAHA.118.038312.
Article PubMed PubMed Central Google Scholar
Bertaglia E, Anselmino M, Zorzi A, Russo V, Toso E, Peruzza F, et al. NOACs and atrial fibrillation: incidence and predictors of left atrial thrombus in the real world. Int J Cardiol. 2017;249:179–83.
Article PubMed Google Scholar
Brambatti M, Darius H, Oldgren J, Clemens A, Noack HH, Brueckmann M, et al. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: results from the RE-LY trial. Int J Cardiol. 2015;196:127–31. https://doi.org/10.1016/j.ijcard.2015.05.141.
Article PubMed Google Scholar
Caldeira D, Costa J, Fernandes RM, Pinto FJ, Ferreira JJ. Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis. J Interv Card Electrophysiol. 2014a;40(3):277–84. https://doi.org/10.1007/s10840-014-9930-y.
Article PubMed Google Scholar
Caldeira D, Barra M, Santos AT, de Abreu D, Pinto FJ, Ferreira JJ, et al. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart. 2014b;100(7):550–6. https://doi.org/10.1136/heartjnl-2013-305288.
Article CAS PubMed Google Scholar
Calkins H, Willems S, Gerstenfeld EP, Schilling R, Hohnloser SH, Okumura K, et al. Uninterrupted Dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med. 2017;376(17):1627–36. https://doi.org/10.1056/NEJMoa1701005.
Article CAS PubMed Google Scholar
Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. [published correction appears in Eur Heart J. 2013 Mar;34(10):790] [published correction appears in Eur Heart J. 2013 Sep;34(36):2850–1]. Eur Heart J. 2012;33(21):2719–47. https://doi.org/10.1093/eurheartj/ehs253.
Article PubMed Google Scholar
Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016;37(14):1145–53. https://doi.org/10.1093/eurheartj/ehv466.
Article PubMed Google Scholar
Camm AJ, Fox KAA, Peterson E. Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention. Europace. 2018;20(1):1–11. https://doi.org/10.1093/europace/eux086.
Article PubMed Google Scholar
Caturano A, Galiero R, Pafundi PC. Atrial fibrillation and stroke. A review on the use of vitamin K antagonists and novel oral anticoagulants. Medicina (Kaunas). 2019;55(10):E617. https://doi.org/10.3390/medicina55100617.
Article Google Scholar
Chao TF, Wang KL, Liu CJ, Lin YJ, Chang SL, Lo LW, et al. Age threshold for increased stroke risk among patients with atrial fibrillation: a nationwide cohort study from Taiwan. J Am Coll Cardiol. 2015;66(12):1339–47. https://doi.org/10.1016/j.jacc.2015.07.026.
Article PubMed Google Scholar
Coleman CI, Peacock WF, Bunz TJ, Alberts MJ. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and previous stroke or transient ischemic attack. Stroke. 2017;48(8):2142–9. https://doi.org/10.1161/STROKEAHA.117.017474.
Article CAS PubMed Google Scholar
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation [published correction appears in N Engl J Med. 2010 Nov 4;363(19):1877]. N Engl J Med. 2009;361(12):1139–51. https://doi.org/10.1056/NEJMoa0905561.
Article CAS PubMed Google Scholar
Connolly SJ, Vallentin L, Yusuf S. Additional events in the RE-LY trial. N Engl J Med. 2014;371(15):1464–5. https://doi.org/10.1056/NEJMc1407908.
Article PubMed Google Scholar
Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. https://doi.org/10.1093/eurheartj/ehz486.
Article PubMed Google Scholar
Cove CL, Albert CM, Andreotti F, Badimon L, Van Gelder IC, Hylek EM. Female sex as an independent risk factor for stroke in atrial fibrillation: possible mechanisms. Thromb Haemost. 2014;111(3):385–91. https://doi.org/10.1160/TH13-04-0347.
Article CAS PubMed Google Scholar
Czuprynska J, Patel JP, Arya R. Current challenges and future prospects in oral anticoagulant therapy. Br J Haematol. 2017;178(6):838–51. https://doi.org/10.1111/bjh.14714.
Article CAS PubMed Google Scholar
Dalgaard F, Pieper K, Verheugt F, Camm AJ, Fox KA, Kakkar AK, et al. GARFIELD-AF model for prediction of stroke and major bleeding in atrial fibrillation: a Danish nationwide validation study. BMJ Open. 2019;9(11):e033283. Published 2019 Nov 11. https://doi.org/10.1136/bmjopen-2019-033283.
Article PubMed PubMed Central Google Scholar
Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126(20):2381–91. https://doi.org/10.1161/CIRCULATIONAHA.112.115410.
Article CAS PubMed Google Scholar
Ding WY, Harrison S, Gupta D, Lip GYH, Lane DA. Stroke and bleeding risk assessments in patients with atrial fibrillation: concepts and controversies. Front Med (Lausanne). 2020;7:54. Published 2020 Feb 21. https://doi.org/10.3389/fmed.2020.00054.
Article Google Scholar
Elhosseiny S, Al Moussawi H, Chalhoub JM, Lafferty J, Deeb L. Direct oral anticoagulants in cirrhotic patients: current evidence and clinical observations. Can J Gastroenterol Hepatol. 2019;2019:4383269. Published 2019 Jan 8. https://doi.org/10.1155/2019/4383269.
Article PubMed PubMed Central Google Scholar
Ezekowitz JA, Lewis BS, Lopes RD, Wojdyla DM, McMurray JJV, Hanna M, et al. Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother. 2015;1(2):86–94. https://doi.org/10.1093/ehjcvp/pvu024.
Article CAS PubMed Google Scholar
Fadhlullah AA, Abdalgbar AA, Altalhi HK. Non rheumatic atrial fibrillation as risk of stroke. Am J Intern Med. 2016;4(6):117–9. https://doi.org/10.11648/j.ajim.20160406.15.
Article Google Scholar
Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2005;112(12):1687–91. https://doi.org/10.1161/CIRCULATIONAHA.105.553438.
Article PubMed PubMed Central Google Scholar
Fang MC, Go AS, Chang Y, Borowsky L, Pomernacki NK, Singer DE, ATRIA Study Group, et al. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2008;51(8):810–5. https://doi.org/10.1016/j.jacc.2007.09.065.
Article PubMed PubMed Central Google Scholar
Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (anticoagulation and risk factors in atrial fibrillation) study. J Am Coll Cardiol. 2011;58(4):395–401. https://doi.org/10.1016/j.jacc.2011.03.031.
Article PubMed PubMed Central Google Scholar
Fox KAA, Lucas JE, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, et al. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open. 2017;7(12):e017157. Published 2017 Dec 21. https://doi.org/10.1136/bmjopen-2017-017157.
Article PubMed PubMed Central Google Scholar
Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish atrial fibrillation cohort study. Eur Heart J. 2015;36(5):297–306. https://doi.org/10.1093/eurheartj/ehu139.
Article PubMed Google Scholar
Fu S, Zhou S, Luo L, Ye P. R_2(GFR)CHADS₂ and R_2(GFR)CHA₂DS₂VASc schemes improved the performance of CHADS₂ and CHA₂DS₂VASc scores in death risk stratification of Chinese older patients with atrial fibrillation. Clin Interv Aging. 2017;12:1233–8. Published 2017 Aug 8. https://doi.org/10.2147/CIA.S138405.
Article CAS PubMed PubMed Central Google Scholar
Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011;57(11):e101–98. https://doi.org/10.1016/j.jacc.2010.09.013.
Article CAS PubMed Google Scholar
Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA. 2001;285(22):2864–70. https://doi.org/10.1001/jama.285.22.2864.
Article CAS PubMed Google Scholar
Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Richet MW, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of atrial fibrillation (NRAF). Am Heart J. 2006;151(3):713–9. https://doi.org/10.1016/j.ahj.2005.04.017.
Article PubMed Google Scholar
Galgani A, Palleria C, Iannone LF, De Sarro G, Giorgi FS, Maschio M, et al. Pharmacokinetic interactions of clinical interest between direct oral anticoagulants and antiepileptic drugs. Front Neurol. 2018;9:1067. https://doi.org/10.3389/fneur.2018.01067.eCollection.2018.
Article PubMed PubMed Central Google Scholar
Garkina SV, Vavilova TV, Lebedev DS, Mikhaylov EN. Compliance and adherence to oral anticoagulation therapy in elderly patients with atrial fibrillation in the era of direct oral anticoagulants. J Geriatr Cardiol. 2016;13(9):807–10. https://doi.org/10.11909/j.issn.1671-5411.2016.09.010.
Article PubMed PubMed Central Google Scholar
Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR real-world data task force report. Value Health. 2007;10(5):326–35. https://doi.org/10.1111/j.1524-4733.2007.00186.x.
Article PubMed Google Scholar
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. ENGAGE AF-TIMI 48 investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104. https://doi.org/10.1056/NEJMoa1310907.
Article CAS PubMed Google Scholar
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92. https://doi.org/10.1056/NEJMoa1107039.
Article CAS PubMed Google Scholar
Graves KG, May HT, Knowlton KU, Muhlestein JB, Jacobs V, Lappé DL, et al. Improving CHA2DS2-VASc stratification of non-fatal stroke and mortality risk using the Intermountain Mortality Risk Score among patients with atrial fibrillation. Open Heart. 2018;5(2):e000907. Published 2018 Nov 17. https://doi.org/10.1136/openhrt-2018-000907.
Article PubMed PubMed Central Google Scholar
Guo Y, Wang H, Zhao X, Zhang Y, Zhang D, Ma J, et al. Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation. Int J Cardiol. 2013;168(5):4678–84. https://doi.org/10.1016/j.ijcard.2013.07.179.
Article PubMed Google Scholar
Hayashi K, Tsuda T, Nomura A, Fujino N, Nohara A, Sakata K, et al. Impact of B-type natriuretic peptide level on risk stratification of thromboembolism and death in patients with non valvular atrial fibrillation—the Hokuriku-plus AF registry. Circ J. 2018;82(5):1271–8. https://doi.org/10.1253/circj.CJ-17-1085.
Article CAS PubMed Google Scholar
Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hackeet W, et al. Updated European heart rhythm association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467–507. https://doi.org/10.1093/europace/euv309.
Article PubMed Google Scholar
Hernandez AV, Bradley G, Khan M, Fratoni A, Gasparini A, Roman YM, et al. Rivaroxaban versus warfarin and renal outcomes in non-valvular atrial fibrillation patients with diabetes [published online ahead of print, 2019 Aug 20]. Eur Heart J Qual Care Clin Outcomes. 2019:qcz047. https://doi.org/10.1093/ehjqcco/qcz047.
Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy. Circulation. 2012;125(13):1605–16. https://doi.org/10.1161/CIRCULATIONAHA.111.038729.
Article CAS PubMed Google Scholar
Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE trial (Apixaban for the prevention of stroke in subjects with atrial fibrillation). J Am Coll Cardiol. 2013;61(22):2274–84. https://doi.org/10.1016/j.jacc.2012.11.082.
Article CAS PubMed Google Scholar
Hijazi Z, Lindbäck J, Alexander JH, Hanna M, Held C, Hylek EM, et al. ARISTOTLE and STABILITY investigators. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016a;37(20):1582–90. https://doi.org/10.1093/eurheartj/ehw054.
Article PubMed PubMed Central Google Scholar
Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, et al. The novel biomarker-based ABC (age, biomarkers, clinical history) -bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016b;387(10035):2302–11. https://doi.org/10.1016/S0140-6736(16)00741-8.
Article CAS PubMed Google Scholar
Hippisley-Cox J, Coupland C, Brindle P. Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. BMJ. 2013;346:f2573. Published 2013 May 2. https://doi.org/10.1136/bmj.f2573.
Article PubMed PubMed Central Google Scholar
Horne BD, May HT, Kfoury AG, Renlund DG, Renlund DG, Muhlestein JB, Lappé DL, et al. The intermountain risk score (including the red cell distribution width) predicts heart failure and other morbidity endpoints. Eur J Heart Fail. 2010;12(11):1203–13. https://doi.org/10.1093/eurjhf/hfq115.
Article PubMed Google Scholar
Hum J, Shatzel JJ, Jou JH, Deloughery TG. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol. 2017;98(4):393–7. https://doi.org/10.1111/ejh.12844.
Article CAS PubMed Google Scholar
Intagliata NM, Henry ZH, Maitland H, Shah NL, Argo CK, Northup PG, et al. Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation. Dig Dis Sci. 2016;61(6):1721–7. https://doi.org/10.1007/s10620-015-4012-2.
Article CAS PubMed Google Scholar
Jacobs V, May HT, Bair TL, Crandall BG, Cutler MJ, Day JD, et al. Long-term population-based cerebral ischemic event and cognitive outcomes of direct oral anticoagulants compared with warfarin among long-term anticoagulated patients for atrial fibrillation. Am J Cardiol. 2016;118(2):210–4. https://doi.org/10.1016/j.amjcard.2016.04.039.
Article PubMed Google Scholar
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. [published correction appears in J Am Coll Cardiol. 2019 Jul 30;74(4):599]. J Am Coll Cardiol. 2019;74(1):104–32. https://doi.org/10.1016/j.jacc.2019.01.011.
Article PubMed Google Scholar
Käräjämäki AJ, Pätsi OP, Savolainen M, Kesäniemi YA, Huikuri H, Ukkola O. Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA Study). PLoS One. 2015;10(11):e0142937. Published 2015 Nov 16. https://doi.org/10.1371/journal.pone.0142937.
Article CAS PubMed PubMed Central Google Scholar
Kato ET, Giugliano RP, Ruff CT, Koretsune Y, Yamashita T, Kiss RG, et al. Efficacy and safety of Edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2016;5(5):e003432. Published 2016 May 20. https://doi.org/10.1161/JAHA.116.003432.
Article PubMed PubMed Central Google Scholar
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016a;37(38):2893–962. https://doi.org/10.1093/eurheartj/ehw210.
Article PubMed Google Scholar
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016b;18(11):1609–78. https://doi.org/10.1093/europace/euw295.
Article PubMed Google Scholar
Kooiman J, van Hagen N, Iglesias Del Sol A, Planken EV, Lip GY, van der Meer FJM, et al. The HAS-BLED score identifies patients with acute venous thromboembolism at high risk of major bleeding complications during the first six months of anticoagulant treatment. PLoS One. 2015;10(4):e0122520. Published 2015 Apr 23.
Article PubMed PubMed Central Google Scholar
Larsen TB, Rasmussen LH, Skjøth F, Due KM, Callréus T, Rosenzweig M, et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol. 2013;61(22):2264–73. https://doi.org/10.1016/j.jacc.2013.03.020.
Article CAS PubMed Google Scholar
Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjøth F, Lane DA, Lip GY. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. Am J Med. 2014;127(12):1172–8.e5. https://doi.org/10.1016/j.amjmed.2014.07.023.
Article CAS PubMed Google Scholar
Lau WC, Chan EW, Cheung CL, Sing CW, Man KKC, Lip GYH, et al. Association between Dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation. JAMA. 2017;317(11):1151–8. https://doi.org/10.1001/jama.2017.1363.
Article CAS PubMed Google Scholar
Lee SR, Choi EK, Park CS, Han KD, Jung JH, Oh S, et al. Direct oral anticoagulants in patients with nonvalvular atrial fibrillation and low body weight. J Am Coll Cardiol. 2019;73(8):919–31. https://doi.org/10.1016/j.jacc.2018.11.051.
Article CAS PubMed Google Scholar
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72. https://doi.org/10.1378/chest.09-1584.
Article PubMed Google Scholar
Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European heart rhythm association, endorsed by the European Society of Cardiology Working Group on thrombosis. Europace. 2011a;13(5):723–46. https://doi.org/10.1093/europace/eur126.
Article PubMed Google Scholar
Lip GYH, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score. J Am Coll Cardiol. 2011b;57(2):173–80. https://doi.org/10.1016/j.jacc.2010.09.024.
Article CAS PubMed Google Scholar
Lip GY, Tse HF, Lane DA. Atrial fibrillation. Lancet. 2012;379(9816):648–61. https://doi.org/10.1016/S0140-6736(11)61514-6.
Article PubMed Google Scholar
Lip GYH, Nielsen PB, Skjøth F, Lane DA, Rasmussen LH, Larsen TB. The value of the European society of cardiology guidelines for refining stroke risk stratification in patients with atrial fibrillation categorized as low risk using the anticoagulation and risk factors in atrial fibrillation stroke score: a nationwide cohort study. Chest. 2014;146(5):1337–46. https://doi.org/10.1378/chest.14-0533.
Article PubMed Google Scholar
Lip GYH, Pan X, Kamble S, Kawabata H, Mardekian J, Masseria C, et al. Major bleeding risk among nonvalvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real-world” observational study in the United States. Int J Clin Pract. 2016;70(9):752–63. https://doi.org/10.1111/ijcp.12863.
Article CAS PubMed PubMed Central Google Scholar
Lip GYH, Skjøth F, Nielsen PB, Kjældgaard JN, Larsen TB. The HAS-BLED, ATRIA, and ORBIT bleeding scores in atrial fibrillation patients using non-vitamin K antagonist oral anticoagulants. Am J Med. 2018;131(5):574.e13–27. https://doi.org/10.1016/j.amjmed.2017.11.046.
Article Google Scholar
López-López JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;359:j5058. https://doi.org/10.1136/bmj.j5058.
Article PubMed PubMed Central Google Scholar
Macle L, Cairns JA, Andrade JG, Mitchell LB, Nattel S, Verma A, CCS Atrial Fibrillation Guidelines Committee. The 2014 atrial fibrillation guidelines companion: a practical approach to the use of the Canadian cardiovascular society guidelines. Can J Cardiol. 2015;31(10):1207–18. https://doi.org/10.1016/j.cjca.2015.06.005.
Article PubMed Google Scholar
Marietta M, Ageno W, Artoni A, De Candia E, Gresele P, Marchetti M, et al. COVID-19 and haemostasis: a position paper from Italian society on thrombosis and Haemostasis (SISET). Blood Transfus. 2020;18(3):167–9. https://doi.org/10.2450/2020.0083-20.
Article PubMed PubMed Central Google Scholar
Maura G, Blotière PO, Bouillon K, Billionnet C, Ricordeau P, Alla F, et al. Comparison of the short-term risk of bleeding and arterial thromboembolic events in atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Circulation. 2015;132(13):1252–60. https://doi.org/10.1161/CIRCULATIONAHA.115.015710.
Article CAS PubMed PubMed Central Google Scholar
McAlister FA, Wiebe N, Hemmelgarn BR. Time in therapeutic range and stability over time for warfarin users in clinical practice: a retrospective cohort study using linked routinely collected health data in Alberta, Canada. BMJ Open. 2018;8(1):e016980. https://doi.org/10.1136/bmjopen-2017-016980.
Article PubMed PubMed Central Google Scholar
Melillo E, Carbone A, Rago A, Papa AA, D’Onofrio A, Nigro G, et al. Update on direct oral anticoagulants in atrial fibrillation patients undergoing cardiac interventional procedures: from clinical trials to real-world evidence. J Cardiovasc Pharmacol. 2020;75(3):185–99. https://doi.org/10.1097/FJC.0000000000000786.
Article CAS PubMed Google Scholar
Mitchell A, Watson M, Welsh T, McGrogan A. Effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists for people aged 75 years and over with atrial fibrillation: a systematic review and meta-analyses of observational studies. J Clin Med. 2019;8(4):554. Published 2019 Apr 24. https://doi.org/10.3390/jcm8040554.
Article CAS PubMed Central Google Scholar
Mostofsky E, Wellenius GA, Noheria A, Levitan EB, Burger MR, Schlaug G, et al. Renal function predicts survival in patients with acute ischemic stroke. Cerebrovasc Dis. 2009;28(1):88–94. https://doi.org/10.1159/000219302.
Article PubMed PubMed Central Google Scholar
NHFA CSANZ Atrial Fibrillation Guideline Working Group, Brieger D, Amerena J, Bajorek B, Chan KH, Connell C, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and new Zealand: Australian clinical guidelines for the diagnosis and Management of Atrial Fibrillation 2018. Heart Lung Circ. 2018;27(10):1209–66. https://doi.org/10.1016/j.hlc.2018.06.1043.
Article Google Scholar
O’Donoghue ML, Ruff CT, Giugliano RP, Murphy SA, Grip LT, Mercuri MF, et al. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation. Eur Heart J. 2015;36(23):1470–7. https://doi.org/10.1093/eurheartj/ehv014.
Article CAS PubMed Google Scholar
O'Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015;36(46):3258–64. https://doi.org/10.1093/eurheartj/ehv476.
Article CAS PubMed PubMed Central Google Scholar
Okumura K, Tomita H, Nakai M, Kodani E, Akao M, Suzuki S, et al. Risk factors associated with ischemic stroke in japanese patients with nonvalvular atrial fibrillation. JAMA Netw Open. 2020;3(4):e202881. Published 2020 Apr 1. https://doi.org/10.1001/jamanetworkopen.2020.2881.
Article PubMed PubMed Central Google Scholar
Olesen JB, Torp-Pedersen C. Stroke risk in atrial fibrillation: do we anticoagulate CHADS2 or CHA2DS2-VASc ≥1, or higher? Thromb Haemost. 2015;113(6):1165–9. https://doi.org/10.1160/TH15-02-0154.
Article PubMed Google Scholar
Olsen FJ, Christensen LM, Krieger DW, Højberg S, Høst N, Karlsen FM, et al. Relationship between left atrial strain, diastolic dysfunction and subclinical atrial fibrillation in patients with cryptogenic stroke: the SURPRISE echo substudy. Int J Cardiovasc Imaging. 2020;36(1):79–89. https://doi.org/10.1007/s10554-019-01700-y.
Article PubMed Google Scholar
Omran H, Bauersachs R, Rubenacker S, Goss F, Hammerstingl C. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK online bRiDging REgistRy (BORDER). Thromb Haemost. 2012;108(1):65–73. https://doi.org/10.1160/TH11-12-0827.
Article CAS PubMed Google Scholar
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91. https://doi.org/10.1056/NEJMoa1009638.
Article CAS PubMed Google Scholar
Pelliccia F, Tanzilli G, Schiariti M, Viceconte N, Greco C, Gaudio C. I nuovi anticoagulanti orali nel mondo reale: il valore aggiunto dei dati dei registri e degli studi osservazionali. Focus su apixaban [Real-world data on novel oral anticoagulants: the added value of registries and observational studies. Focus on apixaban]. G Ital Cardiol (Rome). 2016;17(12 Suppl 3):3S–21S. https://doi.org/10.1714/2642.27146.
Article Google Scholar
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey. Chest. 2010;138(5):1093–100. https://doi.org/10.1378/chest.10-0134.
Article PubMed Google Scholar
Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, et al. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF. J Am Heart Assoc. 2016;5(3):e002197. Published 2016 Mar 8. https://doi.org/10.1161/JAHA.115.002197.
Article PubMed PubMed Central Google Scholar
Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment. Thromb Haemost. 2009;101(5):938–42.
Article CAS PubMed Google Scholar
Prídavková D, Samoš M, Bolek T, Škorňová I, Žolková J, Kubisz P, et al. Type 2 diabetes, atrial fibrillation, and direct oral anticoagulation. J Diabetes Res. 2019;2019:5158308. Published 2019 Dec 6. https://doi.org/10.1155/2019/5158308.
Article CAS PubMed PubMed Central Google Scholar
Proietti R, Porto I, Levi M, Leo A, Russo V, Kalfon E, et al. Risk of pocket hematoma in patients on chronic anticoagulation with warfarin undergoing electrophysiological device implantation: a comparison of different peri-operative management strategies. Eur Rev Med Pharmacol Sci. 2015;19:1461–79.
CAS PubMed Google Scholar
Proietti M, Senoo K, Lane DA, Lip GYH. Major bleeding in patients with non-valvular atrial fibrillation: impact of time in therapeutic range on contemporary bleeding risk scores. Sci Rep. 2016;6:24376. Published 2016 Apr 12. https://doi.org/10.1038/srep24376.
Article CAS PubMed PubMed Central Google Scholar
Rago A, Papa AA, Cassese A, Arena G, Magliocca MCG, D’onofrio A, et al. Clinical performance of Apixaban vs. vitamin K antagonists in patients with atrial fibrillation undergoing direct electrical current cardioversion: a prospective propensity score-matched cohort study. Am J Cardiovasc Drugs. 2019a;19:421–7.
Article CAS PubMed Google Scholar
Rago A, Papa AA, Cassese A, Arena G, Magliocca MCG, D'Onofrio A, et al. Clinical performance of Apixaban vs. vitamin K antagonists in patients with atrial fibrillation undergoing direct electrical current cardioversion: a prospective propensity score-matched cohort study. Am J Cardiovasc Drugs. 2019b;19(4):421–7. https://doi.org/10.1007/s40256-019-00341-9.
Article CAS PubMed Google Scholar
Raschi E, Bianchin M, Ageno W, De Ponti R, De Ponti F. Risk-benefit profile of direct-acting oral anticoagulants in established therapeutic indications: an overview of systematic reviews and observational studies. Drug Saf. 2016;39(12):1175–87. https://doi.org/10.1007/s40264-016-0464-3.
Article CAS PubMed PubMed Central Google Scholar
Risk Factors for Stroke and Efficacy. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials [published correction appears in Arch Intern Med 1994 Oct 10;154(19):2254]. Arch Intern Med. 1994;154(13):1449–57.
Article Google Scholar
Roldan V, Marin F, Manzano-Fernandez S, Fernández H, Gallego P, Valdés M, et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost. 2013;109(5):956–60. https://doi.org/10.1160/TH13-01-0054.
Article CAS PubMed Google Scholar
Roldan V, Vilchez JA, Manzano-Fernandez S, Jover E, Galvez J, Puche CM, et al. Usefulness of N-terminalpro-B-type natriuretic peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation. Stroke. 2014;45(3):696–701. https://doi.org/10.1161/STROKEAHA.113.003338.
Article CAS PubMed Google Scholar
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62. https://doi.org/10.1016/S0140-6736(13)62343-0.
Article CAS PubMed Google Scholar
Russo V, Bianchi V, Cavallaro C, Vecchione F, De Vivo S, Santangelo L, et al. Efficacy and safety of dabigatran in a “real-life” population at high thromboembolic and haemorrhagic risk: Data from MonaldiCare registry. Eur Rev Med Pharmacol Sci. 2015;19:3961–7.
CAS PubMed Google Scholar
Russo V, Di Napoli L, Bianchi V, Tavoletta V, De Vivo S, Cavallaro C, et al. A new integrated strategy for direct current cardioversion in non-valvular atrial fibrillation patients using short-term rivaroxaban administration: the MonaldiVert real life experience. Int J Cardiol. 2016;224:454–5.
Article PubMed Google Scholar
Russo V, Rago A, Proietti R, Di Meo F, Papa AA, Calabrò P, et al. Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence. Ther Adv Drug Saf. 2017a;8:67–75.
Article CAS PubMed Google Scholar
Russo V, Rago A, D’onofrio A, Nigro G. The clinical performance of dabigatran in the Italian real-life experience. J Cardiovasc Med (Hagerstown). 2017b;18:922–3.
Article Google Scholar
Russo V, Rago A, Papa AA, Meo FD, Attena E, Golino P, et al. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with malignancy: clinical practice experience in a single institution and literature review. Semin Thromb Hemost. 2018a;44:370–6.
Article CAS PubMed Google Scholar
Russo V, Rago A, Papa AA, D’onofrio A, Golino P, Nigro G. Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study. J Thromb Thrombolysis. 2018b;45:206–12.
Article CAS PubMed Google Scholar
Russo V, Rago A, Papa AA, Bianchi V, Tavoletta V, DE Vivo S, et al. Budget impact analysis of rivaroxaban vs. warfarin anticoagulation strategy for direct current cardioversion in non-valvular atrial fibrillation patients: the MonaldiVert economic study. Minerva Cardioangiol. 2018c;66:1–5.
PubMed Google Scholar
Russo V, Carbone A, Attena E, Rago A, Mazzone C, Proietti R, et al. Clinical benefit of direct Oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic heart valves. Clin Ther. 2019a;41(12):2549–57. https://doi.org/10.1016/j.clinthera.2019.10.008.
Article CAS PubMed Google Scholar
Russo V, Bottino R, Rago A, Micco PD, D’onofrio A, Liccardo B, et al. Atrial fibrillation and malignancy: the clinical performance of non-vitamin K oral anticoagulants—a systematic review. Semin Thromb Hemost. 2019b;45:205–14.
Article CAS PubMed Google Scholar
Russo V, Attena E, Mazzone C, Melillo E, Rago A, Galasso G, et al. Real-life performance of edoxaban in elderly patients with atrial fibrillation: a multicenter propensity score-matched cohort study. Clin Ther. 2019c;41(8):1598–604. https://doi.org/10.1016/j.clinthera.2019.04.041.
Article CAS PubMed Google Scholar
Russo V, Carbone A, Rago A, Golino P, Nigro G. Direct oral anticoagulants in octogenarians with atrial fibrillation: it is never too late. J Cardiovasc Pharmacol. 2019d;73(4):207–14. https://doi.org/10.1097/FJC.0000000000000661.
Article CAS PubMed Google Scholar
Russo V, Rago A, Proietti R, Attena E, Rainone C, Crisci M, et al. Safety and efficacy of triple antithrombotic therapy with Dabigatran versus vitamin K antagonist in atrial fibrillation patients: a pilot study. Biomed Res Int. 2019e;13:5473240.
Google Scholar
Russo V, Vio R, Proietti R. Stroke, dementia, and atrial fibrillation: from pathophysiologic association to pharmacological implications. Medicina (Kaunas). 2020a;56(5):227. https://doi.org/10.3390/medicina56050227.
Article Google Scholar
Russo V, Paccone A, Rago A, Maddaloni V, Iafusco D, Proietti R, et al. Apixaban in a morbid obese patient with atrial fibrillation: a clinical experience using the plasmatic drug evaluation. J Blood Med. 2020b;11:77–81. PMID: 32184692; PMCID: PMC7061727. https://doi.org/10.2147/JBM.S229526.
Article PubMed PubMed Central Google Scholar
Russo V, Attena E, Rago A, Melillo E, Di Micco P, Papa AA, et al. Clinical outcome of Edoxaban vs. vitamin K antagonists in patients with atrial fibrillation and diabetes mellitus: results from a multicenter, propensity-matched, real-world cohort study. J Clin Med. 2020c;9(6):E1621. Published 2020 May 27. https://doi.org/10.3390/jcm9061621.
Article CAS PubMed Google Scholar
Russo V, Attena E, Di Maio M, Mazzone C, Carbone A, Parisi V, et al. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study. J Thromb Thrombolysis. 2020d;49(1):42–53. https://doi.org/10.1007/s11239-019-01923-9.
Article CAS PubMed Google Scholar
Russo V, Rago A, Laezza N, Di Micco P, Giannetti L, Atripaldi L et al. Edoxaban in elderly patient with morbid obesity and atrial fibrillation: the role of plasma levels evaluation for selecting the appropriate dose. Monaldi Arch Chest Dis. 2020e;90(1). https://doi.org/10.4081/monaldi.2020.1224.
Saito Y, Okumura Y, Nagashima K, Fukamachi D, Yokoyama K, Matsumotoet N, et al. Impact of the fibrosis-4 index on risk stratification of cardiovascular events and mortality in patients with atrial fibrillation: findings from a Japanese Multicenter Registry. J Clin Med. 2020;9(2):584. Published 2020 Feb 21. https://doi.org/10.3390/jcm9020584.
Article CAS PubMed Central Google Scholar
Sakuma I, Uchiyama S, Atarashi H, Inoue H, Kitazono T, Yamashita T, et al. Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND study sub-analysis. [published correction appears in heart vessels. 2019 Aug 2]. Heart Vessels. 2019;34(11):1839–51. https://doi.org/10.1007/s00380-019-01425-x.
Article PubMed Google Scholar
Sato Y, Yoshihisa A, Kanno Y, Watanabe S, Yokokawa T, Abeet S, et al. Liver stiffness assessed by Fibrosis-4 index predicts mortality in patients with heart failure. Open Heart. 2017;4(1):e000598. Published 2017 Apr 28. https://doi.org/10.1136/openhrt-2017-000598.
Article PubMed PubMed Central Google Scholar
Savarese G, Giugliano RP, Rosano GM, McMurray J, Magnani G, Filippatos G, et al. Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis. JACC Heart Fail. 2016;4(11):870–80. https://doi.org/10.1016/j.jchf.2016.07.012.
Article PubMed Google Scholar
Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D'Agostino RB Sr, et al. Development of a risk score for atrial fibrillation (Framingham heart study): a community-based cohort study. Lancet. 2009;373(9665):739–45. https://doi.org/10.1016/S0140-6736(09)60443-8.
Article PubMed PubMed Central Google Scholar
Schulman S, Kearon C, Subcommittee on control of anticoagulation of the scientific and standardization Committee of the International Society on thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4. https://doi.org/10.1111/j.1538-7836.2005.01204.x.
Article CAS PubMed Google Scholar
Shin SY, Han S-J, Kim J-S, Im SI, Shim J, Ahn J, et al. Identification of markers associated with development of stroke in “Clinically Low-Risk” atrial fibrillation patients. J Am Heart Assoc. 2019;8(21):e012697. https://doi.org/10.1161/JAHA.119.012697.
Article PubMed PubMed Central Google Scholar
Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc. 2013;2(3):e000250. Published 2013 Jun 21. https://doi.org/10.1161/JAHA.113.000250.
Article PubMed PubMed Central Google Scholar
Smith JG, Wieloch M, Koul S, Braun O, Lumsden J, Rydell E, et al. Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score. EuroIntervention. 2012;8(6):672–8. https://doi.org/10.4244/EIJV8I6A105.
Article PubMed Google Scholar
Stabile G, Russo V, Rapacciuolo A, De Divitiis M, De Simone A, Solimene F, et al. Transesophagealechocardiograpy in patients with persistent atrial fibrillation undergoing electrical cardioversion on new oral anticoagulants: a multi center registry. Int J Cardiol. 2015;184:283–4.
Article PubMed Google Scholar
Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–93. https://doi.org/10.1093/eurheartj/ehy136.
Article CAS PubMed Google Scholar
Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study. J Stroke Cerebrovasc Dis. 1995;5(3):147–57. https://doi.org/10.1016/S1052-3057(10)80166-1.
Article Google Scholar
Tezuka Y, Iguchi M, Hamatani Y, Ogawa H, Esato M, Tsuji H, et al. Association between relative wall thickness of left ventricle and incidence of thromboembolism in patients with non-valvular atrial fibrillation: The Fushimi AF Registry [published online ahead of print, 2020 Jan 16]. Eur Heart J Qual Care Clin Outcomes. 2020;qcaa003. https://doi.org/10.1093/ehjqcco/qcaa003
The Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. Arch Intern Med. 1997;157(11):1237–40.
Article Google Scholar
Tufano A, Galderisi M. Can echocardiography improve the prediction of thromboembolic risk in atrial fibrillation? Evidences and perspectives [published online ahead of print, 2020 Mar 2]. Intern Emerg Med. 2020. https://doi.org/10.1007/s11739-020-02303-5.
Vafaie M, Giannitsis E, MuellerHennessen M, Biener M, Makarenko E, Yueksel B, et al. High-sensitivity cardiac troponin T as an independent predictor of stroke in patients admitted to an emergency department with atrial fibrillation. PLoS One. 2019;14(2):e0212278. Published 2019 Feb 12. https://doi.org/10.1371/journal.pone.0212278.
Article CAS PubMed PubMed Central Google Scholar
Van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GY. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost. 2011;9(1):39–48. https://doi.org/10.1111/j.1538-7836.2010.04085.x.
Article PubMed Google Scholar
van Zyl M, Abdullah HM, Noseworthy PA, Siontis KC. Stroke prophylaxis in patients with atrial fibrillation and end-stage renal disease. J Clin Med. 2020;9(1):123. Published 2020 Jan 2. https://doi.org/10.3390/jcm9010123.
Article CAS PubMed Central Google Scholar
Verdecchia P, D'Onofrio A, Russo V, Fedele F, Adamo F, Benedetti G, et al. Persistence on apixaban in atrial fibrillation patients: a retrospective multicentre study. J Cardiovasc Med (Hagerstown). 2019;20(2):66–73. https://doi.org/10.2459/JCM.0000000000000744.
Article CAS Google Scholar
Wigle P, Hein B, Bernheisel CR. Anticoagulation: updated guidelines for outpatient management. Am Fam Physician. 2019;100(7):426–34.
PubMed Google Scholar
Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GY. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and metaanalysis of randomized trials. Eur J Heart Fail. 2015;17(11):1192–200. https://doi.org/10.1002/ejhf.343.
Article CAS PubMed Google Scholar
Yao X, Tangri N, Gersh BJ, Sangaralingham LR, Shah ND, Nath KA, et al. Renal outcomes in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2017;70(21):2621–32. https://doi.org/10.1016/j.jacc.2017.09.1087.
Article PubMed Google Scholar
Zachary AS, Richter SK. Direct oral anticoagulants for stroke prevention in atrial fibrillation: treatment outcomes and dosing in special populations. Ther Adv Cardiovasc Dis. 2018;12(9):247–62. https://doi.org/10.1177/1753944718787384.
Article CAS Google Scholar
Zheng LH, Liu SY, Hu F, Liang EP, Wu LM, Wang HL, et al. Association between big endothelin-1 and CHADS₂/CHA₂DS₂-VASc scores in non-valvular atrial fibrillation. J Geriatr Cardiol. 2019;16(11):812–7. https://doi.org/10.11909/j.issn.1671-5411.2019.11.003.
Article PubMed PubMed Central Google Scholar
Zhu WG, Xiong QM, Hong K. Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation. Tex Heart Inst J. 2015a;42(1):6–15. https://doi.org/10.14503/THIJ-14-4353.
Article CAS PubMed PubMed Central Google Scholar
Zhu W, He W, Guo L, Wang X, Hong K. The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol. 2015b;38(9):555–61. https://doi.org/10.1002/clc.22435.
Article PubMed PubMed Central Google Scholar
Zhu W, Wan R, Liu F, Hu J, Huang L, Li J, et al. Relation of body mass index with adverse outcomes among patients with atrial fibrillation: a meta-analysis and systematic review. J Am Heart Assoc. 2016;5(9):e004006. Published 2016 Sep 9. https://doi.org/10.1161/JAHA.116.004006.
Article PubMed PubMed Central Google Scholar

Download references

Author information

Authors and Affiliations

Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy
Alfredo Caturano, Raffaele Galiero, Serenella Spiezia & Pia Clara Pafundi

Authors

Alfredo Caturano
View author publications
You can also search for this author in PubMed Google Scholar
Raffaele Galiero
View author publications
You can also search for this author in PubMed Google Scholar
Serenella Spiezia
View author publications
You can also search for this author in PubMed Google Scholar
Pia Clara Pafundi
View author publications
You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

Cardiac Rehabilitation Unit Ospedale, Sacra Famiglia Fatebenefratelli, Erba, Italy
Riccardo Proietti
McGill University, Montreal, QC, Canada
Ahmed AlTurki
Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padova, Italy
Nicola Ferri
Department of Medical Translational Sciences, University of Campania “Luigi Vanvitelli” - Monaldi Hospital, Naples, Italy
Vincenzo Russo
Division of Cardiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
T. Jared Bunch

Rights and permissions

Reprints and permissions

Copyright information

About this chapter

Cite this chapter

Caturano, A., Galiero, R., Spiezia, S., Pafundi, P.C. (2021). Risk Stratification For and Use of DOAC Therapies for Stroke Prevention in Patient with Atrial Fibrillation. In: Proietti, R., AlTurki, A., Ferri, N., Russo, V., Bunch, T.J. (eds) Direct Oral Anticoagulants. Springer, Cham. https://doi.org/10.1007/978-3-030-74462-5_6

Download citation

DOI: https://doi.org/10.1007/978-3-030-74462-5_6
Published: 29 June 2021
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-74461-8
Online ISBN: 978-3-030-74462-5
eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics